Debbie Rigby takes a look at the latest in research news, focusing on COVID-19
There currently are no data to recommend the use of HCQ as prophylaxis for COVID-19. The HCQ shortage not only will limit availability to patients with COVID-19 if efficacy is truly established but also represents a real risk to patients with rheumatiod arthritis and systemic lupus erythematosus who depend on HCQ for their survival.
Ann Intern Med. 2020.
COVID-19 is associated with a high inflammatory burden that can induce vascular inflammation, myocarditis, and cardiac arrhythmias. A large proportion of affected patients to date have been reported to have underlying cardiovascular disease.
JAMA Cardiol. Published online March 27, 2020.
Pre-existing cardiovascular disease (CVD) increases the morbidity and mortality of COVID-19, and COVID-19 itself causes serious cardiac sequelae. Common acute cardiac manifestations of COVID-19 include left ventricular dysfunction, heart failure, arrhythmias and acute coronary syndromes. Patients with pre-existing CVD are more susceptible to life-threatening SARS-CoV-2 infection.
Med J Aust, published online 3 April 2020.
NICE guideline on managing symptoms provides advice to health professionals on the management of cough, fever, breathlessness and anxiety, delirium and agitation in those with COVID-19. It includes approaches for managing these symptoms such as considering the use of paracetamol in people with fever. People are advised to first treat a mild cough with simple measures and should also avoid lying on their back as this can make coughing, which helps clear the lungs, more difficult.
NICE Guideline, published 3 April 2020.